AN ACT

 

1Amending the act of April 14, 1972 (P.L.233, No.64), entitled
2"An act relating to the manufacture, sale and possession of
3controlled substances, other drugs, devices and cosmetics;
4conferring powers on the courts and the secretary and
5Department of Health, and a newly created Pennsylvania Drug,
6Device and Cosmetic Board; establishing schedules of
7controlled substances; providing penalties; requiring
8registration of persons engaged in the drug trade and for the
9revocation or suspension of certain licenses and
10registrations; and repealing an act," further providing for
11schedules of controlled substances.

12The General Assembly of the Commonwealth of Pennsylvania
13hereby enacts as follows:

<-14Section 1. Section 4(1)(vii) of the act of April 14, 1972
15(P.L.233, No.64), known as The Controlled Substance, Drug,
16Device and Cosmetic Act, amended June 20, 2011 (P.L.86, No.7),
17is amended and the paragraph is amended by adding a subparagraph
18to read:

19Section 4. Schedules of Controlled Substances.--The
20following schedules include the controlled substances listed or

1to be listed by whatever official name, common or usual name,
2chemical name, or trade name designated.

3(1) Schedule I--In determining that a substance comes within
4this schedule, the secretary shall find: a high potential for
5abuse, no currently accepted medical use in the United States,
6and a lack of accepted safety for use under medical supervision.
7The following controlled substances are included in this
8schedule:

9* * *

10(iii.1) Any compound, except bupropion or compounds listed
11under a different schedule, or compounds used within legitimate
12and approved medical research, structurally derived from 2-
13aminopropan-1-one by substitution at the 1-position with phenyl,
14naphthyl or thiophenen ring systems, whether or not the compound
15is further modified in any of the following ways:

161. By substitution in the ring system to any extent with
17alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl or halide
18substituents whether or not further substituted in the ring
19system by one or more other univalent substituents.

202. By substitution at the 3-position with an acyclic alkyl
21substituent.

223. By substitution at the 2-amino nitrogen atom with alkyl,
23dialkyl, benzyl or methoxybenzyl groups.

244. By inclusion of the 2-amino nitrogen atom in a cyclic
25structure.

26* * *

27(vii) [Synthetic cannabinoids or any material, compound, 
28mixture or preparation which contains any quantity of the 
29following substances, including their analogues, congeners, 
30homologues, isomers, salts and salts of analogues, congeners, 

1homologues and isomers, as follows:

21. CP 47,497 and homologues, 2-[(1R,3S)-3-
3hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol).

42. HU-210, [(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-
5methyloctan-2-yl)-6a,7,10, 10a-tetrahydrobenzo[c] chromen-1-
6ol)].

73. HU-211, (dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-6,6-
8dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
9tetrahydrobenzo[c]chromen-1-ol).

104. JWH-018, 1-Pentyl-3-(1-naphthoyl)indole.

115. JWH-019, 1-Hexyl-3-(1-naphthoyl)indole.

126. JWH-073, 1-Butyl-3-(1-naphthoyl)indole.

137. JWH-200, (1-(2-morpholin-4-ylethyl)indol-3-yl)-
14naphthalen-1-ylmethanone.

158. JWH-250, 1-pentyl-3-(2-methoxyphenylacetyl)indole.]

16Synthetic cannabinoids including any material, compound, mixture
17or preparation that is not listed as a controlled substance in
18Schedule I through V, is not a Federal Food and Drug
19Administration approved drug or used within legitimate and
20approved medical research and which contains any quantity of the
21following substances, their salts, isomers, whether optical
22positional or geometric, analogues, homologues and salts of
23isomers, analogues and homologues, unless specifically excepted,
24whenever the existence of these salts, isomers, analogues,
25homologues and salts of isomers, analogues and homologues if
26possible within the specific chemical designation:

271. Tetrahydrocannabinols or tetrahydrocannabinols which is
28naturally contained in a plant of the genus cannabis as well as
29synthetic equivalents of the substances contained in the plant
30or in the resinous extractives of Cannabis or synthetic

1substances, derivatives and their isomers with similar chemical
2structure and or pharmacological activity such as the following:

3(A) Delta 1 cis or trans tetrahydrocannabinol and their
4optical isomers.

5(B) Delta 6 cis or trans tetrahydrocannabinol and their
6optical isomers.

7(C) Delta 3, 4 cis or their trans tetrahydrocannabinol and
8their optical isomers.

92. Naphthoxylindoles or any compound containing a 3-(-1-
10napthoyl) indole structure with substitution at the nitrogen
11atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
12alkenyl, cycloalkymethyl, cycloalkylethyl, 1-(N-methyl-2-
13piperidinyl) methyl, 2-(4-morpholinyl) ethyl, 1-(N-methyl-2-
14pyrrolidinyl) methyl, 1-(N-methyl-3-morpholinyl) methyl or
15(terahydropyran-4-yl) methyl group, whether or not further
16substituted in the indole ring to any extent and whether or not
17substituted in the naphthyl ring to any extent. This shall
18include the following:

19(A) JWH 015.

20(B) JWH 019.

21(C) JWH 073.

22(D) JWH 081.

23(E) JWH 122.

24(F) JWH 200.

25(G) JWH 210.

26(H) JWH 398.

27(I) AM2201.

28(J) WIN 55 212.

293. Naphylmethylindoles or any compound containing a 1H-
30indol-3-yl-(1-naphthyl) methanae methane structure with a

1substition at the nitrogen atom of the indole ring by an alkyl,
2haloalkyl, cyanoalkyl, alkenyl, cycloalkymethyl,
3cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, 2-(4-
4morpholinyl) ethyl, 1-(N-methyl-2-pyrrolidinyl) methyl, 1-(N-
5methyl-3-morpholinyl) methyl or (tetrahydropyran-4-yl) methyl
6group, whether or not further substituted in the indole ring to
7any extent and whether or not substituted in the naphthyl ring
8to any extent. This shall include JWH 175 and JWH 184.

94. Naphthoylpyrroles or any compound containing a 3-(1-
10naphthoyl) pyrrole structure with substitution at the nitrogen
11atom of the pyrrole ring by alkyl, haloalkyl, cyanoalykl,
12alkenyl, cycloalkymethyl, cycloalkylethyl, 1-(N-methyl-2-
13piperidinyl) methyl, 2-(4-morpholinyl) ethyl, 1-(N-methyl-2-
14pyrrolidinyl) methyl, 1-(N-methyl-3-morpholinyl) methyl or
15(tetrahydropyran-4-yl) methyl group, whether or not further
16substituted in the pyrrole ring to any extent and whether or not
17substituted in the naphthyl ring to any extent. This shall
18include JWH 307.

195. Naphthylmethylindenes or any compound containing a
20naphthylideneindene structure with substitution at the 3-
21position of the indene ring by an alkyl, haloalkyl, cyanoalkyl,
22alkenyl, cycloalkymethyl, cycloalkylethyl, 1-(N-methyl-2-
23piperidinyl) methyl, 2-(4-morpholinyl) ethyl, 1-(N-methyl-2-
24pyrrolidinyl) methyl, 1-(N-methyl-3-morpholinyl)methyl or
25(tetraydropyran-4-yl) methyl group, whether or not further
26substituted in the indene ring to any extent and whether or not
27substituted in the naphthyl ring to any extent. This shall
28include JWH 176.

296. Phenylacetylindoles or any compound containing a 3-
30phenylacetylindole structure with substitution at the nitrogen

1atom of the indole ring by alkyl, haloalkyl, cyanoalkyl,
2alkenyl, cycloalkymethyl, cycloalkylethyl, 1-(N-methyl-2-
3piperidinyl) methyl, 2-(4-morpholinyl) ethyl, 1-(N-methyl-2-
4pyrrolidinyl) methyl, 1-(N-methyl-3-morpholinyl) methyl or
5(tetrahydropyan-4-yl) methyl group, whether or not further
6substituted in the indole ring to any extent and whether or not
7substituted in the phenyl ring to any extent. This shall include
8the following:

9(A) RCS-8 or SR-18.

10(B) JWH 250.

11(C) JWH 203.

12(D) JWH 251.

13(E) JWH 302.

147. Cyclohexylphenols or any compound containing a 2-(3-
15hydroxycyclohexyl) phenol structure with a substitution at the
165-position of the phenolic ring by alkyl, haloalkyl, cyanoalkyl,
17alkenyl, cycloalkymethyl, cycloalkylethyl, 1-(N-methyl-2-
18piperininyl) methyl, 2-(4-morpholinyl) ethyl, 1-(N-methyl-2-
19pyrrolidinyl) methyl, 1-(N-methyl-3-morpholinyl) methyl or
20(tetrahydropyran-4-yl) methyl group, whether or not substituted
21in the cyclohexyl ring to any extent. This shall include the
22following:

23(A) CP 47, 497 and its homologues and analogs.

24(B) Cannabicyclohexanol.

25(C) CP 55, 940.

268. Benzoylindoles or any compound containing a 3-(benzoyl)
27indole structure with substitution at the nitrogren atom of the
28indole ring by alkyl, haloalkyl, cyanoalkyl, alkenyl,
29cycloalkymethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)
30methyl, 2-(4-morpholinyl) ethyl, 1-(N-methyl-2-pyrrolidinyl)

1methyl, 1-(N-methyl-3- morpholinyl) methyl or (tetrahydropyran-
24-yl) methyl group, whether or not further substituted in the
3indole ring to any extent and whether or not substituted in the
4phenyl ring to any extent. This shall include the following:

5(A) Am 694.

6(B) Pravadoline WIN 48098.

7(C) RCS 4.

8(D)AM-679.

99. [2,3-Dihydro-5 methyl-3-(4-morpholinylmethyl ) pyrrolo
10[1,2,3-de]-1, 4-benzoxazin-6-yl]-1-napthalenymethanone. This
11shall include WIN 55, 212-2.

1210. (6aR,10aR)-9-(hydroxymethyl)-6, 6-dimethyl-3(2-
13methyloctan-2-yl)-6a, 7, 10, 10a-tetrahydrobenzo [c]chromen-1-
14old 7370. This shall include HU 210 and HU 211.

1511. Adamantoylindoles or any compound containing a 3-(-
161adamtoyl) indole structure with substitution at the nitrogen
17atom of the indole ring by alkyl, haloalkyl, cyanoalkyl,
18alkenyl, cycloalkymethyl, cycloalkylethyl, 1-(N-methyl-2-
19piperidinyl) methyl, 2-(4-morpholinyl) ethyl, 1-(N-methyl-2-
20pyrrolidinyl) methyl, 1-(N-methyl-3-morpholinyl) methyl or
21(tetrahydropyran-4-yl) methyl group, whether or not further
22substituted in the adamantyl ring system of any extent. This
23shall include AM 1248.

2412. Tetramethylcyclopropanoylindoles or any compound
25containing a 3-tetramethylcyclopropylindole structure with
26substitution at the nitrogen atom of the indole ring by analkyl,
27haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,
28cycloalkylethy, 1-(N-methyl-2-piperidinyl) methyl, 2-(4-
29morpholinyl) ethyl, 1-(N-methyl-2-pyrrolidinyl) methyl, 1-(N-
30methyl-3-morpholinyl) methyl or (tetrahydropyran-4-yl) methyl

1group whether or not further substituted in the indole ring to
2any extent and whether or not substituted in the
3tetramethylcyclopropanoyl ring to any extent. This shall include
4UR-144.

513. Any other synthetic chemical compound that is a
6cannabinoid receptor agonist and mimics the pharmacological
7effect of the naturally occurring cannabinoids that is not
8listed in Schedules II through V, not an Federal Food and Drug
9Administration approved drug or used within legitimate, approved
10medical research.

11* * *

12Section 2. This act shall take effect in 60 days.

<-13Section 1. Section 4(1)(vii) of the act of April 14, 1972
14(P.L.233, No.64), known as The Controlled Substance, Drug,
15Device and Cosmetic Act, amended June 23, 2011 (P.L.36, No.7),
16is amended and the paragraph is amended by adding a subparagraph
17to read:

18Section 4. Schedules of Controlled Substances.--The
19following schedules include the controlled substances listed or
20to be listed by whatever official name, common or usual name,
21chemical name, or trade name designated.

22(1) Schedule I--In determining that a substance comes within
23this schedule, the secretary shall find: a high potential for
24abuse, no currently accepted medical use in the United States,
25and a lack of accepted safety for use under medical supervision.
26The following controlled substances are included in this
27schedule:

28* * *

29(iii.1) Any compound, except bupropion or compounds listed
30under a different schedule, or compounds used within legitimate

1and approved medical research, structurally derived from 2-
2aminopropan-1-one by substitution at the 1-position with
3monocyclic or fused polycyclic ring systems, whether or not the
4compound is further modified in any of the following ways:

51. By substitution in the ring system to any extent with
6alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl or halide
7substituents whether or not further substituted in the ring
8system by one or more other univalent substituents.

92. By substitution at the 3-position with an acyclic alkyl
10substituent.

113. By substitution at the 2-amino nitrogen atom with alkyl,
12dialkyl, benzyl or methoxybenzyl groups.

134. By inclusion of the 2-amino nitrogen atom in a cyclic
14structure.

15* * *

16(vii) [Synthetic cannabinoids or any material, compound,
17mixture or preparation which contains any quantity of the
18following substances, including their analogues, congeners,
19homologues, isomers, salts and salts of analogues, congeners,
20homologues and isomers, as follows:

211. CP 47,497 and homologues, 2-[(1R,3S)-3-
22hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol).

232. HU-210, [(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-
24methyloctan-2-yl)-6a,7,10, 10a-tetrahydrobenzo[c] chromen-1-
25ol)].

263. HU-211, (dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-6,6-
27dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
28tetrahydrobenzo[c]chromen-1-ol).

294. JWH-018, 1-Pentyl-3-(1-naphthoyl)indole.

305. JWH-019, 1-Hexyl-3-(1-naphthoyl)indole.

16. JWH-073, 1-Butyl-3-(1-naphthoyl)indole.

27. JWH-200, (1-(2-morpholin-4-ylethyl)indol-3-yl)-
3naphthalen-1-ylmethanone.

48. JWH-250, 1-pentyl-3-(2-methoxyphenylacetyl)indole.]

5Synthetic cannabinoids including any material, compound, mixture
6or preparation that is not listed as a controlled substance in
7Schedule I through V, is not a Federal Food and Drug
8Administration approved drug or used within legitimate and
9approved medical research and which contains any quantity of the
10following substances, their salts, isomers, whether optical
11positional or geometric, analogues, homologues and salts of
12isomers, analogues and homologues, unless specifically exempted,
13whenever the existence of these salts, isomers, analogues,
14homologues and salts of isomers, analogues and homologues if
15possible within the specific chemical designation:

161. Tetrahydrocannabinols meaning tetrahydrocannabinols which
17are naturally contained in a plant of the genus Cannabis as well
18as synthetic equivalents of the substances contained in the
19plant or in the resinous extractives of Cannabis or synthetic
20substances, derivatives and their isomers with analogous
21chemical structure and or pharmacological activity such as the
22following:

23(A) Delta-1 cis or trans tetrahydrocannabinol and their
24optical isomers.

25(B) Delta-6 cis or trans tetrahydrocannabinol and their
26optical isomers.

27(C) Delta-3,4 cis or their trans tetrahydrocannabinol and
28their optical isomers.

292. Naphthoylindoles or any compound containing a 3-(-1-
30napthoyl) indole structure with substitution at the nitrogen

1atom of the indole ring whether or not further substituted in
2the indole ring to any extent and whether or not substituted in
3the naphthyl ring to any extent. This shall include the
4following:

5(A) JWH 015.

6(B) JWH 018.

7(C) JWH 019.

8(D) JWH 073.

9(E) JWH 081.

10(F) JWH 122.

11(G) JWH 200.

12(H) JWH 210.

13(I) JWH 398.

14(J) AM 2201.

15(K) WIN 55,212.

163. Naphylmethylindoles or any compound containing a 1H-
17indol-3-yl-(1-naphthyl) methane structure with a substition at
18the nitrogen atom of the indole ring whether or not further
19substituted in the indole ring to any extent and whether or not
20substituted in the naphthyl ring to any extent. This shall
21include JWH 175 and JWH 184.

224. Naphthoylpyrroles or any compound containing a 3-(1-
23naphthoyl) pyrrole structure with substitution at the nitrogen
24atom of the pyrrole ring whether or not further substituted in
25the pyrrole ring to any extent and whether or not substituted in
26the naphthyl ring to any extent. This shall include JWH 147 and
27JWH 307.

285. Naphthylmethylindenes or any compound containing a
29naphthylideneindene structure with substitution at the 3-
30position of the indene ring whether or not further substituted

1in the indene ring to any extent and whether or not substituted
2in the naphthyl ring to any extent. This shall include JWH 176.

36. Phenylacetylindoles or any compound containing a 3-
4phenylacetylindole structure with substitution at the nitrogen
5atom of the indole ring whether or not further substituted in
6the indole ring to any extent and whether or not substituted in
7the phenyl ring to any extent. This shall include the following:

8(A) RCS-8, SR-18 or BTM-8.

9(B) JWH 250.

10(C) JWH 203.

11(D) JWH 251.

12(E) JWH 302.

137. Cyclohexylphenols or any compound containing a 2-(3-
14hydroxycyclohexyl) phenol structure with a substitution at the
155-position of the phenolic ring whether or not substituted in
16the cyclohexyl ring to any extent. This shall include the
17following:

18(A) CP 47,497 and its homologues and analogs.

19(B) Cannabicyclohexanol.

20(C) CP 55,940.

218. Benzoylindoles or any compound containing a 3-(benzoyl)
22indole structure with substitution at the nitrogren atom of the
23indole ring whether or not further substituted in the indole
24ring to any extent and whether or not substituted in the phenyl
25ring to any extent. This shall include the following:

26(A) AM 694.

27(B) Pravadoline WIN 48,098.

28(C) RCS 4.

29(D) AM 679.

309. [2,3-Dihydro-5 methyl-3-(4-morpholinylmethyl)pyrrolo

1[1,2,3-de]-1, 4-benzoxazin-6-yl]-1-napthalenymethanone. This
2shall include WIN 55,212-2.

310. Dibenzopyrans or any compound containing a 11-hydroxy-
4delta 8-tetrahydrocannabinol structure with substitution on the
53-pentyl group. This shall include HU-210, HU-211, JWH 051 and
6JWH 133.

711. Adamantoylindoles or any compound containing a 3-(-1-
8adamantoyl) indole structure with substitution at the nitrogen
9atom of the indole ring whether or not further substituted in
10the adamantoyl ring system to any extent. This shall include AM
111248.

1212. Tetramethylcyclopropylindoles or any compound containing
13a 3-tetramethylcyclopropylindole structure with substitution at
14the nitrogen atom of the indole ring whether or not further
15substituted in the indole ring to any extent and whether or not
16substituted in the tetramethylcyclopropyl ring to any extent.
17This shall include UR-144 and XLR-11.

1813. N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide. This
19shall include AKB48.

2014. Any other synthetic chemical compound that is a
21cannabinoid receptor type 1 agonist as demonstrated by binding
22studies and functional assays that is not listed in Schedules
23II, III, IV and V, not Federal Food and Drug Administration
24approved drug or used within legitimate, approved medical
25research.

26* * *

27Section 2. This act shall take effect immediately.

 

See other bills
under the
same topic